UK woman killed by rare IVF risk, Ovarian Hyperstimulation Syndrome
By BBC News,
BBC News
| 04. 13. 2005
Temilola Akinbolagbe, 33, from Plumstead, south London, collapsed at a bus stop after developing Ovarian Hyperstimulation Syndrome (OHSS).
The potentially fatal form of the condition affects about one per cent of women undergoing IVF, although a less severe form is more common.
Experts believe this was the first such death from OHSS in the UK.
Mild and moderate forms of OHSS have been reported to affect up to 20% of women undergoing ovarian induction, which mimics the production of normal hormones.
It is believed there have been three other deaths from the condition in the last 30 years.
Mrs Akinbolagbe, from Plumstead, south London, started to feel ill after receiving fertility treatment.
She was taken to hospital immediately, but suffered a massive heart attack.
Mrs Akinbolagbe's life support machine was turned off five days later.
Her husband, Samuel Ifaturoti, said his wife had been "very positive" about the fertility treatment.
'Not a particular risk'
Gynaecologist John Parsons said staff at Kings College Hospital, where she had received her fertility treatment, were all shocked by Mrs Akinbolagbe's death.
He said: "We...
Related Articles
By Katie Hunt, CNN | 07.30.2025
Scientists are exploring ways to mimic the origins of human life without two fundamental components: sperm and egg.
They are coaxing clusters of stem cells – programmable cells that can transform into many different specialized cell types – to form...
By Rob Stein, NPR [cites CGS' Katie Hasson] | 08.06.2025
A Chinese scientist horrified the world in 2018 when he revealed he had secretly engineered the birth of the world's first gene-edited babies.
His work was reviled as reckless and unethical because, among other reasons, gene-editing was so new...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...
By Hannah Devlin, The Guardian | 07.05.2025
Scientists are just a few years from creating viable human sex cells in the lab, according to an internationally renowned pioneer of the field, who says the advance could open up biology-defying possibilities for reproduction.
Speaking to the Guardian, Prof...